Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Dreyling

Showing results (181-190 of 336) with videos related to

Pageof 34
Sort By:
Leukemia & Lymphoma|June 18, 2014
Changes in the diagnosis and treatment of patients with low grade lymphoma in Germany: years 2006-2009Christian Schmidt, Guenter Fingerle-Rowson, Angelika Boehme, et al.
Blood|December 3, 2017
Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL NetworkSietse M Aukema, Eva Hoster, Andreas Rosenwald, et al.
Journal of Hematopathology|August 12, 2009
Genomic deletion and promoter methylation status of Hypermethylated in Cancer 1 (HIC1) in mantle cell lymphomaHeike Stöcklein, Grit Hutter, Jörg Kalla, et al.
Infection|October 4, 2022
Treatment, outcome and re-vaccination of patients with SARS-CoV-2 vaccine-associated immune thrombocytopeniaMichael Ruzicka, Sonja Wurm, Lars Lindner, et al.
Blood|July 31, 2004
The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study GroupRoswitha Forstpointner, Martin Dreyling, Roland Repp, et al.
BMC Cancer|August 25, 2025
The MCL elderly III trial protocol: an international, randomized, open-label phase II trial to investigate the combinations of venetoclax, ibrutinib and rituximab or bendamustine, ibrutinib and rituximab in patients with treatment naive mantle cell lymphoma not eligible for dose-intensive treatmentStephanie Herold, Christian Schmidt, Carlo Visco, et al.
Journal of Personalized Medicine|November 26, 2025
Gene Expression Profiling Provides an Improved Characterization of <i>CD79B</i>-Mutated Diffuse Large B-Cell LymphomasLuis Grossmann, Wolfgang Jagla, Marcus Bettstetter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 9, 2008
Five-gene model to predict survival in mantle-cell lymphoma using frozen or formalin-fixed, paraffin-embedded tissueElena Hartmann, Verònica Fernàndez, Victor Moreno, et al.
Leukemia|July 26, 2023
Clinical outcome of Mantle Cell Lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression)Gabriel Scheubeck, Linmiao Jiang, Olivier Hermine, et al.
Haematologica|June 17, 2021
Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results of the phase III MabCute studySimon Rule, Wolney Gois Barreto, Javier Briones, et al.
Pageof 34

Showing results (181-190 of 336) with videos related to

Sort By:
Pageof 34
Leukemia & Lymphoma|June 18, 2014
Changes in the diagnosis and treatment of patients with low grade lymphoma in Germany: years 2006-2009Christian Schmidt, Guenter Fingerle-Rowson, Angelika Boehme, et al.
Blood|December 3, 2017
Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL NetworkSietse M Aukema, Eva Hoster, Andreas Rosenwald, et al.
Journal of Hematopathology|August 12, 2009
Genomic deletion and promoter methylation status of Hypermethylated in Cancer 1 (HIC1) in mantle cell lymphomaHeike Stöcklein, Grit Hutter, Jörg Kalla, et al.
Infection|October 4, 2022
Treatment, outcome and re-vaccination of patients with SARS-CoV-2 vaccine-associated immune thrombocytopeniaMichael Ruzicka, Sonja Wurm, Lars Lindner, et al.
Blood|July 31, 2004
The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study GroupRoswitha Forstpointner, Martin Dreyling, Roland Repp, et al.
BMC Cancer|August 25, 2025
The MCL elderly III trial protocol: an international, randomized, open-label phase II trial to investigate the combinations of venetoclax, ibrutinib and rituximab or bendamustine, ibrutinib and rituximab in patients with treatment naive mantle cell lymphoma not eligible for dose-intensive treatmentStephanie Herold, Christian Schmidt, Carlo Visco, et al.
Journal of Personalized Medicine|November 26, 2025
Gene Expression Profiling Provides an Improved Characterization of <i>CD79B</i>-Mutated Diffuse Large B-Cell LymphomasLuis Grossmann, Wolfgang Jagla, Marcus Bettstetter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 9, 2008
Five-gene model to predict survival in mantle-cell lymphoma using frozen or formalin-fixed, paraffin-embedded tissueElena Hartmann, Verònica Fernàndez, Victor Moreno, et al.
Leukemia|July 26, 2023
Clinical outcome of Mantle Cell Lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression)Gabriel Scheubeck, Linmiao Jiang, Olivier Hermine, et al.
Haematologica|June 17, 2021
Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results of the phase III MabCute studySimon Rule, Wolney Gois Barreto, Javier Briones, et al.
Pageof 34